← Statins × cardiovascular events

TrialThe New England journal of medicine2009

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Robert J Glynn et al.PubMed ↗Full text ↗Publisher ↗

  • Rosuvastatin, 20 mg per daylooks good hereLower symptomatic venous thromboembolism, lower provoked venous thromboembolism, lower deep-vein thrombosis only.Randomised, small.

What the trial testedrandomised · 94 people · 2009

Randomised vs placebo

Probably lowered symptomatic venous thromboembolism

−43%−63% to −14%

rosuvastatin, 20 mg per day vs placebo

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.57, 95% CI 0.37–0.86

Randomised vs placebo

Probably lowered provoked venous thromboembolism

−48%−72% to −4%

rosuvastatin, 20 mg per day vs placebo

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.52, 95% CI 0.28–0.96

Randomised vs placebo

Probably lowered deep-vein thrombosis only

−55%−75% to −21%

rosuvastatin, 20 mg per day vs placebo

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.45, 95% CI 0.25–0.79

Range includes no effect

No clear effect on unprovoked venous thromboembolism

−39%−65% to +9%

rosuvastatin, 20 mg per day vs placebo

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.35–1.09

+1 more in the walkthrough ↓

Who was studied, and how

300people in the Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study trial, from 2015
94of them with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

rosuvastatin, 20 mg per day
placebo

Probably lowered symptomatic venous thromboembolism−43%

Probably lowered provoked venous thromboembolism−48%

Probably lowered deep-vein thrombosis only−55%

randomised

the abstract, start to end

… (hazard ratio with rosuvastatin, 0.57; 95% confidence interval [CI], 0.37 to 0.86; P=0.007); the corresponding rates for unprovoked venous thromboembolism (i.e., occurring in the absence of a known malignant condition, trauma, hospitalization, or surgery) were 0.10 and 0.17 (hazard ratio, 0.61; 95% CI, 0.35 to 1.09; P=0.09) and for provoked venous thromboembolism (i.e., occurring in patients with cancer or during or shortly after trauma, hospitalization, or surgery), 0.08 and 0.16 (hazard ratio, 0.52; 95% CI, 0.28 to 0.96; P=0.03).

… 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; …

← favours treatmentfavours comparator →
could be chance
Symptomatic venous thromboembolismrosuvastatin, 20 mg per day vs placebo
HR 0.570.37–0.86
Unprovoked venous thromboembolismrosuvastatin, 20 mg per day vs placebo
HR 0.610.35–1.09
Provoked venous thromboembolismrosuvastatin, 20 mg per day vs placebo
HR 0.520.28–0.96
Pulmonary embolismrosuvastatin, 20 mg per day vs placebo
HR 0.770.41–1.45
Deep-vein thrombosis onlyrosuvastatin, 20 mg per day vs placebo
HR 0.450.25–0.79
StatinsCardiovascular events

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

250 papers cite itlatest 60 shown

2009
…
2012
2013
2014
2015
2016
2017
2019
2020
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

3 trials

NCT02428374phase 4300 enrolled2015NCT00239681phase 317,802 enrolled2003NCT04895059phase 136 enrolled2017
Full record →Abstract, authors, funding and every citing paper · PMID 19329822